Background and Objective: The aim of this study is to identify risk factors for mortality in a community-based cohort of nondemented patients with Parkinson disease (PD) during prospective long-term follow-up, while also comparing the effect of motor complications to nonmotor symptoms (NMS) on risk of mortality. Methods: One hundred forty seven nondemented patients with PD (57.1% males; 70.9 + 8.6 years old) were included in this 48 month follow-up, longitudinal, single, evaluation study. Motor and therapy-related complications were assessed using the Unified Parkinson's Disease Rating Scale/part-IV (UPDRS-IV). Non-Motor Symptoms Scale (NMSS) total score was used to assess NMS burden. Cox proportional hazard models were applied to identify independent predictors of mortality during follow-up. Results: Twenty-two patients of 146 (15.1%) died (1 case without information). Both UPDRS-IV and NMSS total scores were higher at baseline in patients with PD who died (3.5 + 3.1 vs 2.4 + 2.4, P ¼ .049 and 96.9 + 58.6 vs 61.9 + 51.0, P ¼ .004, respectively). Unadjusted hazard ratios (HRs) associated with UPDRS-IV and NMSS total scores among those who died during follow-up were 1.171 (95% confidence interval [CI]: 1.012-1.357; P ¼ .035) and 1.008 (95% CI: 1.002-1.013; P ¼ .006), respectively. Independent predictors of mortality during follow-up after adjusting for other covariates were UPDRS-IV (HR: 1.224; 95% CI: 1.002-1.494; P ¼ .047), age (HR: 1.231; 95% CI: 1104-1.374; P < .0001), and comorbidity (Charlson Index; HR: 1.429; 95% CI: 1.023-1.994; P ¼ .036), but not NMSS total score (HR: 1.005; 95% CI: 0.996-1.014; P ¼ .263). Conclusions: Both motor complications (UPDRS-IV) and NMS (NMSS) were associated with mortality at 4 years, being motor complications an independent predictor of it.
Introduction
Parkinson disease (PD), the second most common neurodegenerative disease after Alzheimer disease, is a progressive neurodegenerative disorder causing motor and nonmotor symptoms (NMS) which result in disability, loss of patient autonomy, and caregiver burden. 1 The understanding of PD has changed over recent years, with the disease currently considered to be a neurodegenerative disorder involving a multitude of pathways and neurotransmitters which may explain, in part, the large range of symptoms that patients may experience. 2 Parkinson disease is not only a motor disease. Several different NMS such as pain, fatigue, depression, anxiety, apathy, cognitive, and/or psychotic symptoms are frequently observed and continue to exert a negative impact on quality of life, 3 while also becoming increasingly important in clinical observations of PD. 4 Thus, identifying and quantifying NMS accompanying PD is essential, and several recent publications have investigated the magnitude of the impact of NMS compared to motor symptoms on different important aspects of the disease in patients with PD. 5, 6 Additionally, patients with PD may develop different motor complications along the progression of disease that can increase the risk of fatality. Seeing as mortality is increased in patients with PD, it is necessary to identify whether and how NMS and motor complications may serve as predictors of mortality. Presumably, mortality would be increased in patients with PD with motor complications, as well as several NMS . For example, a fall can result in acute complications and death. However, the increased risk of falling in patients can be attributed to off episodes and/or dyskinesia associated with PD. 7 On the other hand, the risk of falling in patients with PD may also be heightened with some NMS such as dizziness, pain, insomnia, diurnal somnolence, visual hallucinations, and/or depression. 8 Moreover, both motor complications and higher NMS burden are more frequent in patients with advanced stage PD 9,10 who also have a higher risk of mortality (eg, bronchoaspiration). Thus, both motor complications and NMS could contribute to an increased risk of mortality in patients with PD, but the magnitude of the effect of each is not apparent. Thus, ideally identifying motor symptoms and NMS as predictors of mortality in patients with PD in the first steps of the disease (eg, nondemented patients) is critical for preventative PD interventions.
The aim of this study is therefore to identify independent risk factors for short-term mortality in a community-based cohort of nondemented patients with PD during prospective long-term follow-up, specifically with a focus on the effect of motor and therapy-related complications compared to NMS burden on mortality.
Material and Methods
One hundred forty-seven nondemented patients with PD (57.1% males; 70.9 + 8.6 years old) from a Spanish cohort, previously studied in detail, 11 were followed over 4 years (from 2012 to 2016). Although the sample was initially 150 patients with PD, 3 patients were ultimately excluded because a diagnosis different than PD was made in the long term. 11 Comorbidity at baseline was also assessed using the Charlson Index. 12 Finally, the strain on the principal caregiver of the patient was assessed by the Zarit Caregiver Burden Inventory (ZCBI) and Caregiver Strain Index (CSI). 13 The cohort was monitored for mortality over 4 years. The follow-up information was collected by a neurologist specialized in movement disorders (D.S.-G.). The cases without follow-up information over the 4 years were excluded (eg, from May 11, 2012 , to May 11, 2016) . The cause of death was recorded in all cases. For the purpose of the study, the NMSS total score was used as a marker of NMS burden 14 and the UPDRS-IV total score as a marker of motor complications (motor fluctuations and/or dyskinesia) as well as complications related to therapy. 15 In both cases, a higher punctuation indicates a worse status for the aspect assessed. The study (PREMORT-PD, PREdictors of MORTality in Parkinson Disease) was approved by the local ethics committee. All participants (patients and caregivers) signed an informed consent form.
Data were processed using SPSS 21.0 for Windows. Proportions between groups were compared using the w 2 test. Continuous variables have been expressed as mean (standard deviation [SD]) or median and quartiles, depending on whether they were normally distributed, and compared using the Student t test or the Mann-Whitney U test, as appropriate. Cox proportional hazards models were applied to identify independent predictors of mortality during follow-up. Specifically, NMSS and UPDRS-IV total scores were included in the model and other covariates that were shown to hypothetically increase mortality risk were included as well. Values of P < .05 were considered significant.
Results
Twenty-two patients of 146 (15.1%) died (1 case with no information available) within 4 years of follow-up. Infectious cases and complications related to cancer were the most frequent cause of death (Table 1 ). Both UPDRS-IV and NMSS total scores at baseline were higher in patients with PD who died: 3.5 + 3.1 versus 2.4 + 2.4 (P ¼ .049) and 96.9 + 58.6 versus 61.9 + 51.0 (P ¼ .004), respectively (Table 2) . Moreover, age, ON-UPDRS-III, ON-H&Y, PDQ-39SI score, equivalent daily dose of levodopa, and Charlson Index at baseline were higher, and ADLS at baseline was lower in the group of patients with PD who died during the follow-up (Table 2) .
Patients who died during the follow-up presented at baseline a higher score in domains 5 to 8 of the NMSS (attention/memory, gastrointestinal symptoms, urinary symptoms, and sexual dysfunction) and in domain 1 (mobility), 2 (activities of daily living), and 6 (cognition) of the PDQ-39SI ( Table 2) . The percentage of patients presenting with both motor and therapy-related complications and NMS related to different domains of the NMSS (at least 1 item being positive) was higher in all cases among those who died during the follow-up, but it was significant only for cardiovascular symptoms (81.8% vs 59.7%, P ¼ .037) and gastrointestinal symptoms (90.9% vs 66.9%, P ¼ .016; Figure 1A ). When specifically analyzing the relationship between NMS and the risk of death, having only cardiovascular and gastrointestinal symptoms at baseline according to the NMSS was related to death: 18 (19.6%) of 92 and 20 (19.4%) of 103 patients who presented at baseline with at least 1 cardiovascular and gastrointestinal symptom, respectively, died during the follow-up compared to only 4 (7.4%) of 54 (P ¼ .037) and 2 (4.7%) of 43 (P ¼ .016) who did not ( Figure 1B ). The presence of at least 1 gastrointestinal symptom (P ¼ .025) was significantly related to a higher risk of death in Kaplan-Meier analysis ( Figure 2 ). These results were observed for all individualized gastrointestinal symptoms: drooling (NMSS-item 19; P ¼ .032), dysphagia (NMSS-item 20; P < .0001), and constipation (NMSS-item 21; P ¼ .08; Figure 2 ). With regard to strain on the principal caregiver of the patient, ZCBI and CSI scores at baseline were both significantly higher in patients with PD who died ( Table 2) . Unadjusted hazard ratios (HRs) associated with UPDRS-IV and NMSS total scores of those who died during the follow-up were 1 
Discussion
The present study demonstrates that older and more motorcompromised nondemented patients with PD, with more severe motor and therapy-related complications, a higher NMS burden, more severe comorbidity, a higher levodopa equivalent dose, more negative perception of their quality of life, and lowered autonomy to carry out daily activities are at a higher risk of death in the short term. However, only age, motor and therapy-related complications (UPDRS-IV), and comorbidity (Charlson Index) seem to be independent predictors of mortality. This is the first reported instance in which all of these variables have been taken into consideration together and the role of NMS has been assessed by the NMSS to determine their impact on the risk of mortality.
Several factors have been identified as risk predictors of mortality among patients with PD: sociodemographic factors such as old age, late age of onset, and male gender; motor symptoms and axial signs such as gait disorder and motor disease severity; and NMS such as cognitive impairment, dementia, depression, or psychotic symptoms. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] However, to the best of our knowledge, this is the first study in which NMS has been analyzed in detail and in which the effect of NMS burden as a whole has been considered in the analysis. Patients with PD who died during the 4-year follow-up demonstrated an NMSS total score one-third more than those who survived, and specifically these patients had greater impact in cognition (attention/memory), gastrointestinal and urinary functions, and sexual function. Several studies identified dementia as a risk factor for mortality in PD. 19, 31 However, patients included in our study were nondemented at baseline and conversion to mild cognitive impairment or dementia was not evaluated. Nevertheless, cognition was more greatly impacted in patients who died not only in the NMSS but also in the PDQ-39SI, suggesting that subjective patient perception of cognitive problems may be relevant. Depression has been related to mortality in some studies 31 and this was confirmed again in our study in that NMSS-mood/apathy score and BDI were both higher in patients who died (a significant trend). In fact, the percentage of patients who presented different NMS was in all cases higher in the group who died, and clearly the percentage of cases who died was higher when NMS were present. The most consistent relationship was to gastrointestinal symptoms, that is, drooling, dysphagia, and constipation. Dysphagia and drooling increase the risk of bronchoaspiration and secondary death due to injury-related mortality. 34, 35 Thus, the addition of a single, simple question (NMSS-item 20) could be useful in identifying nondemented patients with PD with a 4-fold higher short-term risk of death. Moreover, to have a very severe NMS burden (NMSS > 70), 9 multiply by 3 the probability of death at 4 year.
The present study also sought to also determine whether motor complications or NMS may be seen as a greater risk factor for mortality. Previous studies have shown that NMS have a more negative impact on quality of life than motor symptoms. 5, 6, 11 In this study, both motor symptoms and NMS were more frequent and severe in patients with PD who died, but only UPDRS-IV was an independent predictor of mortality. Moreover, age and comorbidity were independent predictors of mortality as well. Unified Parkinson's Disease Rating Scale/ part-IV motor score (part III) has been reported to predict mortality separately from the effect of other variables in some studies, 36, 37 but motor complications (UPDRS-part IV) were not included. The risk of presenting falls, chocking, and other potential causes of mortality is higher in patients with PD having "off" episodes and dyskinesia. 7 In our study, UPDRS-III (total score) was not a predictor of mortality, while gait problems were. Once again, motor and/or axial problems act as a risk factor for mortality. Moreover, causes and frequency of mortality in this study are in line with previous reports. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Identification of risk factors and causes of mortality in PD is valuable for preventative measures and planning, while also providing venues for treatment with the most impactful outcomes, including prolonged survival. In fact, these predictors should be ideally identified in patients in the first steps of the disease (eg, nondemented patients) to provide ample time for necessary prevention. Thus, while it is challenging to overcome aging, this study suggests promise in controlling comorbidities (eg, hypertension, diabetes, etc) and motor complications with their respective therapies. 38, 39 Finally, caregiver burden has been observed in principal caregivers of patients with dementia, psychotic symptoms, depression, heightened disability, and lowered autonomy over daily functioning. 13, 40, 41 Caregivers' emotional strain is an independent risk factor for mortality among elderly spousal caregivers. 42 However, this study has demonstrated that a higher degree of caregiver is also associated with a higher risk of death, especially in the context of a patient with more advanced and symptomatic PD. Thus, caregiver burden may also be considered as a risk marker of mortality in PD.
Despite the highlighted outcomes, this study has several important limitations. The study was a monocenter study, with a small sample size and no control group for comparison. However, the size of the sample is sufficient for the objective of the study. Attempting to analyze the risk of death was not an objective because a higher risk of mortality compared to the general population has been reported in many studies and is well known. That stated, the results should be replicated in a multicenter study with a larger sample size. Nondemented patients with PD were included according to clinical evaluation in medical records and daily practice assessments, without preference for a particular cognitive screening test. 11 The presented study did succeed in conveying an analysis based on a clearly specified a priori hypothesis and a well-planned regression model, as recommended by best practice methods. In addition, ON state motor function was assessed following a strict protocol. 11 Moreover, predictors of mortality were identified in this cohort at 3 years of follow-up and associated bias cannot be excluded from the subsequent analysis. 12 Still, this is a different analysis and the relationship between NMS and death reported here is something novel in interest. Finally, we recruited a group of patients with PD from the outpatient neurology clinics, and therefore, our results might not be generalized to population-dwelling patients with PD. Also, the application of NMSS has obvious limitations inherent to the use of this type of scales including the fact that the NMSS includes as NMS axial symptoms related to motor status such as dysphagia or drooling (as gastrointestinal symptom) or the limitation for its use with the aim of assessing NMS in patients with cognitive impairment (this is not the case here). However, NMSS is currently the most frequently used for assessing NMS as a whole in patients with PD in clinical practical and also in research, it is recommended by the Movement Disorder Society, 43 and in fact NMSS total score is the principal variable in some randomized trials. 44 In any case, we acknowledge the need to replicate these findings in a population-based survey of unselected patients.
In conclusion, age, comorbidity, and motor and therapyrelated complications (UPDRS-IV) predict mortality in nondemented patients with PD in the short term. Additionally, NMS burden is associated with a higher risk of death, and NMS become more frequent and detrimental in patients with a higher risk of mortality. Gastrointestinal symptoms-especially dysphagia-are the most linked. Further exploration of this relation is necessary in the future.
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